J. Garland
Direktor/Vorstandsmitglied bei DAY ONE BIOPHARMACEUTICALS, INC.
Vermögen: - $ am 30.04.2024
Profil
J.
Scott Garland is an Independent Director at Olema Pharmaceuticals, Inc., ALX Oncology Holdings, Inc., and Day One Biopharmaceuticals, Inc. He previously served as the Chief Executive Officer & Director at PACT Pharma, Inc., President, Chief Executive Officer & Director at Portola Pharmaceuticals LLC, and Chief Commercial Officer at Exelixis, Inc. He also held positions at Karyopharm Therapeutics, Inc., Amgen, Inc., Genentech, Inc., and Relypsa, Inc. Mr. Garland received his undergraduate degree from California Polytechnic State University (San Luis Obispo) and his MBA from The Fuqua School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 | |
| 31.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 | |
| 30.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 | |
| 23.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von J. Garland
| Unternehmen | Position | Beginn |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 17.08.2021 |
| ALX ONCOLOGY HOLDINGS INC. | Direktor/Vorstandsmitglied | 28.11.2022 |
| OLEMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 16.10.2023 |
Ehemalige bekannte Positionen von J. Garland
| Unternehmen | Position | Ende |
|---|---|---|
PACT Pharma, Inc.
 PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA. | Vorstandsvorsitzender | 01.02.2023 |
| PORTOLA PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 01.07.2020 |
| KARYOPHARM THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 21.05.2020 |
| RELYPSA INC | Präsident | 01.10.2018 |
| EXELIXIS, INC. | Corporate Officer/Principal | 31.10.2014 |
Ausbildung von J. Garland
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
| The Fuqua School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| AMGEN INC. | Health Technology |
| CALITHERA BIOSCIENCES, INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
PACT Pharma, Inc.
PACT Pharma, Inc. Pharmaceuticals: MajorHealth Technology PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA. | Health Technology |
